

Subject: Intracytoplasmic Sperm Injection (ICSI)

Guideline #: CG-SURG-35

Publish Date:

07/07/202107/08/20

Status: Revisewed

Last Review Date:

20
05/134/20210

Description

This document addresses the use of intracytoplasmic sperm injection (ICSI) during an infertility treatment cycle, allowing ~~infertile~~ couples ~~with male factor infertility~~ to attain live birth rates, similar to those achieved with in vitro fertilization (IVF) using conventional methods of fertilization.

Note: Please see the following related documents for additional information:

- CG-MED-66 Cryopreservation of Oocytes or Ovarian Tissue
- CG-SURG-34 Diagnostic Infertility Surgery

Clinical Indications

Medically Necessary:

A maximum of three cycles of ICSI per attempted pregnancy is considered **medically necessary** in covered individuals who meet **ANY** of the following criteria:

- A. Severe ~~male factor~~ infertility ~~diagnosed based on due to~~ **any** of the following semen analysis parameters;
1. Asthenozoospermia (less than 40% moving sperm) (see definition section); **or**
 2. Oligozoospermia (less than 15 million/ml); **or**
 3. Teratozoospermia (normal morphology in 4% or fewer observed sperm); **or**

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

- B. Previous IVF treatment cycle has resulted in failed or poor fertilization (equal to or greater than 50% of oocytes unfertilized in a prior cycle); **or**
- C. Anti-sperm antibodies have been documented; **or**
- D. Spinal cord injury individuals requiring electroejaculated sperm; **or**
- E. Surgically retrieved sperm (epididymal or testicular); **or**
- F. When using cryopreserved sperm for individuals in remission from cancer; **or**
- G. When completing preimplantation genetic diagnosis (PGD) (for example, for single gene defect).

Note: Two semen analyses are required prior to categorization of the ~~male~~ infertility. A comprehensive semen analysis must be completed prior to infertility treatment cycles.

Not Medically Necessary:

- A. More than three cycles of ICSI per attempted pregnancy is considered **not medically necessary**.
- B. ICSI is considered **not medically necessary** when the criteria above are not met including, but not limited to all of the following:
 1. Unexplained infertility;
 2. Tubal occlusion;
 3. Advanced maternal age;
 4. Low oocyte yield at retrieval;
 5. Routine insemination of oocytes for IVF.

Coding

The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue’s standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

CPT

89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes
89281	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes

ICD-10 Diagnosis

All diagnoses

When services are Not Medically Necessary:

For the procedure codes listed above when criteria are not met or for situations designated in the Clinical Indications section as not medically necessary.

Discussion/General Information

The American Society of Reproductive Medicine (ASRM) (2020~~15~~) defines infertility as [a disease of the reproductive system with](#) the inability to achieve a successful pregnancy after 12 months or more of regular unprotected intercourse. ~~Male~~ Infertility ~~is defined as~~ [can be caused by](#) the inability to ejaculate or an insufficient number of sperm. Work-up for the diagnosis of infertility should include a comprehensive medical, reproductive, and family history and a physical exam. Laboratory testing and diagnostic evaluation may also be appropriate with emphasis on a systematic, expeditious manner and the least invasive method for diagnosis of infertility.

According to the National Institutes of Health (NIH), approximately one in six couples has difficulty conceiving. It is estimated that ~~male~~ infertility [related to sperm factors occurs](#) in about 30–40% of these cases. The most common cause for ~~infertility in men~~ [reduced sperm production](#) is an enlarged mass of veins in the spermatic cord within the scrotum. The spermatic cord is made up of veins, arteries, lymphatic vessels, nerves, and the duct that carries sperm from the testes to the seminal vesicles.

Normal semen parameters established by the World Health Organization (WHO) laboratory manual for the examination and processing of human semen (2010) are as follows:

- Semen volume: 1.5 ml or more;
- pH: 7.2 or more;

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue’s standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member’s card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

- Sperm concentration: 15 million spermatozoa per ml or more;
- Total sperm number: 39 million spermatozoa per ejaculate or more;
- Total motility (percentage of progressive motility and non-progressive motility): 40% or more motile or 32% or more with progressive motility;
- Vitality: 58% or more live spermatozoa;
- Sperm morphology (normal forms): 4% or more
- pH greater than or equal to 7.2
- Seminal fructose, $\mu\text{mol/ejaculation}$ greater than or equal to 13.

The World Health Organization (2010) considers Severe male factor infertility is due to sperm factors defined by to be severe when any of the following semen analysis parameters are present:

- Oligozoospermia (less than 15 million/ml)
- Asthenozoospermia (less than 40% moving sperm)
- Teratozoospermia (normal morphology in 4% or fewer observed sperm)
- Positive anti-sperm antibodies
- Spinal cord injury individuals requiring electroejaculated sperm
- Surgically retrieved sperm (epididymal or testicular)

ICSI is a potential component of an IVF cycle; this alternate technique has expanded treatment options for ~~male~~ infertility allowing previously infertile couples to conceive. The procedure is completed under a microscope using a microscopic glass needle to inject a single sperm directly into the egg. Once the egg is fertilized, it is transferred to the ~~female partner's~~ uterus. ICSI is used for individuals who have very poor semen quality or lack of sperm in the semen caused by an obstruction or testicular failure. In some cases, sperm may be surgically extracted from the testicles or epididymis for this procedure.

According to the Society for Assisted Reproductive Technology (2008):

If a woman gets pregnant naturally, there is a 1.5% to 3% chance that the baby will have a major birth defect. The chances of birth defects after ICSI are rare. Certain conditions that have been associated with the use of ICSI (Beckwith-Wiedemann syndrome, Angelman syndrome, hypospadias, or sex chromosome

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

abnormalities) are thought to occur in far less than 1% of children conceived using this technique. Some of the problems that caused your infertility may be genetic. Therefore, boys conceived with the use of ICSI may have infertility issues as adults.

Smith and colleagues (2010) reported results from a prospective fertility cohort study of 408 couples undergoing cycle-based treatment in the United States. The authors concluded that cycle-based fertility treatments offer clinically significant increases in the pregnancy rate; however, this benefit does not persist indefinitely.

Couples not achieving a pregnancy with medications alone after two cycles or intrauterine insemination (IUI) after three cycles may be best counseled to pursue a higher level of infertility treatment. Those failing IVF after two cycles may want to consider other treatment strategies, such as donor sperm, donor egg, or further modifications in the IVF or ICSI protocol because additional cycles seem less likely to increase reproductive success as much as earlier cycles.

A 2020 committee opinion of the American Society of Reproductive Medicine and Society for Assisted Reproductive Technology stated that ICSI is a safe and effective treatment for ~~male factor~~ infertility [due to sperm factors](#). The document also stated that ICSI for unexplained fertility, low oocyte yield and advanced maternal age does not improve clinical outcomes. Their opinion included a statement that ICSI may be beneficial for individuals undergoing IVF with preimplantation genetic testing (PGT), fertilization after *in vitro* matured oocytes and cryopreserved oocytes. The authors concluded that the use of ICSI is a safe and effective therapy for the treatment of ~~male factor~~ [related to sperm factors](#); currently there is no data to support the routine use of ICSI for ~~non male factor~~ [other causes of](#) infertility.

Definitions

Azoospermia: Lack of live spermatozoa in the semen; classified as obstructive or nonobstructive depending on whether cause is blockage of the tubules or ducts.

Infertility: [A disease of the reproductive system with the inability to achieve a successful pregnancy after 12 months or more of regular unprotected intercourse.](#)

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

Intracytoplasmic sperm injection (ICSI): A fertility treatment that is used to treat sperm related problems by injecting a single sperm into a mature egg. The fertilized egg is then placed in a woman's uterus or fallopian tube.

Oligospermia: Decreased number of spermatozoa in the semen.

Teratozoospermia: The sperm shape is abnormal and incapable of fertilizing the egg, with normal morphology observed in 4% or fewer sperm.

References

Peer Reviewed Publications:

- 2-1. Anderson JE, Farr SL, Jamieson DJ, et al. Infertility services reported by men in the United States: national survey data. *Fertility and Sterility*. 2009; (6):2466-2470.
- 3-2. Boulet SL, Mehta A, Kissin DM, et al. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. *JAMA*. 2015; 313(3):255-263.
- 4-3. Kathiresan AS, Ibrahim E, Aballa TC, et al. Comparison of in vitro fertilization/intracytoplasmic sperm injection outcomes in male factor infertility patients with and without spinal cord injuries. *Fertil Steril*. 2011; 96(3):562-566.
- 5-4. Pandian Z, Bhattacharya S, Ozturk O, et al. Number of embryos for transfer following in-vitro fertilization or intra-cytoplasmic sperm injection. *Cochrane Database of Systematic Reviews* 2009;(2):CD003416.
- 6-5. Smith JF, Eisenberg ML, Millstein SG, et al. Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States. *Fertil Steril*. 2011; 95:79-84.

Government Agency, Medical Society, and Other Authoritative Publications:

- 2-1. The American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Obstetric Practice Committee on Gynecologic practice. Committee on Genetics. Number 324, November 2005, Reaffirmed 2015. Perinatal risks associated with assisted reproductive technology. *Obstet Gynecol* 2015; 106:1143-1146.
- 3-2. [American Urological Association and American Society for Reproductive Medicine. Diagnosis and treatment of infertility evaluation of the infertile male: a committee opinion. 2015.](#) Available at:

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

- <https://www.asrm.org/news-and-publications/practice-committee-documents/>. Accessed on March 1025, 20210.
3. [American Urological Association and American Society for Reproductive Medicine. Diagnosis and treatment of infertility in men: a committee opinion. October 2020. Available at: https://www.asrm.org/news-and-publications/practice-committee-documents/](https://www.asrm.org/news-and-publications/practice-committee-documents/). Accessed on March 16, 2021.
 4. Cooper TG, Noonan E, von Eckardstein S, World Health Organization reference values for human semen characteristics. Human Reproduction Update. 2010; 16, (3)231-245.
 5. Practice Committee of American Society for Reproductive Medicine and Society for Assisted Reproductive Technology. Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. 202012. Available at: <https://www.asrm.org/news-and-publications/practice-committee-documents/>. Accessed on March 1025, 20210.
 6. Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology. Evaluation of the azoospermic male. Fertil Steril. 2008; 90:74-77.
 7. Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology. The management of infertility due to obstructive azoospermia. Fertil Steril. 2008; 90:121-124.
 8. World Health Organization (WHO) Department of Reproductive Health and Research. WHO laboratory manual for the examination and processing of human semen. Fifth edition. 2010. Available at: <http://www.who.int/reproductivehealth/publications/infertility/9789241547789/en/>. Accessed on March 1025, 20210.

Websites for Additional Information

1. American Society for Reproductive Medicine. Available at: <http://www.asrm.org/>. Accessed on March 1025, 20210.
2. Medline Plus. Male Infertility. Updated AugustFebruary 274, 2020. Available at: <http://www.nlm.nih.gov/medlineplus/maleinfertility.html>. Accessed on March 1025, 20210.

Index

Intracytoplasmic sperm injection (ICSI)

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Intracytoplasmic Sperm Injection (ICSI)

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

History

Status	Date	Action
Revised	05/13/2021	Medical Policy & Technology Assessment Committee (MPTAC) review. Removed reference of sex in MN clinical indications section. Updated Description, Discussion, References and Websites sections. Reformatted Coding section.
Reviewed	05/14/2020	Medical Policy & Technology Assessment Committee (MPTAC) review. Updated References and Websites sections.
Revised	06/06/2019	MPTAC review. Updated formatting in Clinical Indications section. Clarified MN criteria for severe male factor infertility diagnosed based on semen analysis parameter, teratozoospermia. Updated Description, Discussion, Definition, References and Websites sections.
Reviewed	07/26/2018	MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date”. Updated References and Websites sections.
Reviewed	08/03/2017	MPTAC review. Updated Discussion, References and Websites sections.
Reviewed	08/04/2016	MPTAC review. Discussion and Websites sections updated. Removed ICD-9 codes from Coding section. Updated formatting in Clinical Indications section.
Revised	08/06/2015	MPTAC review. Clarified medically necessary abbreviation. Discussion and Websites sections updated.
Reviewed	08/14/2014	MPTAC review. Websites updated.
New	08/08/2013	MPTAC review. Initial document development.

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue’s standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member’s card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.